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1400 | J. Mater. Chem. B, 2014, 2, 140Pulsatile drug release from electrospun
poly(ethylene oxide)–sodium alginate blend
nanoﬁbres†
Abdessamad Y. A. Kaassis,a Neil Young,b Naoko Sano,c Hamid A. Merchant,a
Deng-Guang Yu,d Nicholas P. Chatterton*e and Gareth R. Williams*a
Novel and highly tuneable pulsatile drug delivery systems have been prepared through the electrospinning
of a blend of poly(ethylene oxide) (PEO), sodium alginate (SA), and sodium ibuprofen (SI). The resultant ﬁbres
contain crystallites of SI embedded in a PEO–SA matrix, and rather than being obtained as ﬂat mats on the
collector plate form novel three dimensional structures extending upwards the needle. Fibres were
prepared with a range of loadings of SI and SA. It was found that at pH 6.8 (reminiscent of the intestinal
tract) the ﬁbres dissolve very rapidly, freeing all the embedded drug within ca. 20 minutes. However, at
pH 3 (representative of the stomach pH in the fed state or in older patients) an unusual two stage release
mechanism is seen. This comprises a rapid burst release, followed by a period where no further drug is
released for ca. 120–150 minutes, and then a ﬁnal stage of release freeing the remainder of the drug into
solution. The amount of release in the initial stage, and the length of time between the ﬁrst and ﬁnal
drug release stages, can be controlled by adjusting the SI and SA contents of the ﬁbres respectively. This
results in highly tunable pulsatile release materials.Introduction
Electrospinning is a facile top-down technique permitting the
fabrication of a wide variety of functional nanocomposites. A
solution of a polymer and a functional component is prepared,
usually in a volatile solvent, and expelled from a needle (spin-
neret) towards a metal collector at a controlled rate. A high
potential diﬀerence is applied between the two and this elec-
trical energy causes rapid evaporation of the solvent, resulting
in polymer-based one-dimensional objects with diameters on
the nm scale.1–4 These bres have a number of desirable prop-
erties (e.g. high surface area) which may be tuned by controlling
the processing parameters (voltage applied, needle-to-collector
distance, ow rate, solution concentration, etc.).1
A large number of studies have reported the use of electro-
spinning to produce drug-loaded bres for use as engineeredllege London, 29-39 Brunswick Square,
@ucl.ac.uk; Tel: +44 (0)207 753 5868
ord, Parks Road, Oxford, OX1 3PH, UK
uilding, Newcastle upon Tyne, NE1 7RU,
, University of Shanghai for Science and
Life Sciences and Computing, London
y Road, London, N7 8DB, UK. E-mail:
207 133 4373
tion (ESI) available. See DOI:
0–1407drug delivery systems.1,5–9 The majority of these studies use one-
uid electrospinning, but even in this simple system it is found
that variation of the polymer and processing parameters can
result in a wide range of drug release behaviours. More recently,
more advanced approaches have been employed to develop
bespoke drug delivery proles; these include coaxial electro-
spinning (using two concentric needles, one nested inside
another) and a process combining electrospinning and spray-
ing.10,11 The electrospinning of polymer blends has also been
explored reasonably widely, and has been applied to drug
delivery to achieve a variety of release proles.12–14 Electrospun
materials have successfully been used to modify the rate of drug
release,13 to target release to a particular part of the body such as
the gastrointestinal tract,5 or to deliver biphasic or dual-stage
drug release.10,11 While such release proles can be very useful
in the development of advanced pharmaceutics, they are inap-
propriate if a drug has a high rst-pass eﬀect or if to be eﬀective
it requires very time-specic delivery.15 Time-controlled pulsa-
tile release, in which the drug is released aer a predened time
period, is more appropriate for such applications.
A number of disease states follow biological rhythms.16 For
instance, asthma attacks tend to happen mainly late at night,
following the body's natural circadian cycle, and pain from
rheumatoid arthritis is most intense in the morning. Epilepsy
also oscillates in its implications for patients, in response to
melatonin secretion. To eﬀectively treat these conditions,
precise time-controlled release proles are required. Pulsatile
delivery systems of drugs such as sodium valproate (indicatedThis journal is © The Royal Society of Chemistry 2014
Table 1 The compositions of the ﬁbres prepared in this study. 10 mL
of a 5% w/v PEO–SA solution was added to the amount of ibuprofen
detailed below to prepare spinning solutions
Fibre
ID
Mass SI
(g)
SA conc.
(% w/v)
% PEO
in bre
(w/w)
% SA in
bre
(w/w)
% SI in
bre
(w/w)
F0 0 1.5 76.9 23.1 0
F1 1 1.5 30.3 9.1 60.6
F2 0.2 1.5 58.8 17.6 23.5
F3 0.1 1.5 66.7 20.0 13.3
F4 1 1 31.3 6.3 62.5
F5 1 2 29.4 11.8 58.8
F6 1 2.5 28.6 14.3 57.1
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View Article Onlinefor the treatment of epilepsy) or diltiazem (angina) are hence
much sought aer to enhance patient compliance and improve
clinical outcomes. To date, there are no reports of time-resolved
pulsatile release from electrospun nanobres.
The formation of a system comprising two polymers mixed,
with a drug component loaded, oﬀers the potential to deliver
novel drug release proles even from a single uid electro-
spinning process. If one of these polymers has pH-sensitive
characteristics, then targeted drug release should be possible.
One such polymer is alginic acid, commonly available as its
sodium salt, which dissolves only at elevated pHs. In order to
incorporate sodium alginate (SA) into nanobres, it is necessary
to blend it with a carrier polymer.17 A number of researchers
have developed electrospun bres containing SA blended with
poly(ethylene oxide) (PEO).18–21 Alborzi et al. have used SA–
pectin–PEO bres to stabilise folic acid,22 and Lee and co-
workers have coated poly(vinyl alcohol) bres with alginate for
pH sensitive release.23 In 2012, two sets of researchers inde-
pendently reported the formation of novel electrospun bres
comprising PEO and SA.24,25 Although both teams used the same
building blocks and similar synthetic processes, very diﬀerent
results were obtained: Ma et al. created core–shell nanobres
with a PEO shell and a SA core,25 while Bonino and co-workers
noted the formation of a “mountain” of bres on the collector
plate instead of the at mat normally seen, which they attrib-
uted to the aggregation of SA on the exterior of the bres.24
It is clear therefore that blended PEO–SA bres have inter-
esting properties from an academic viewpoint; in addition, PEO
is a highly suitable polymer for drug delivery systems because it
is classied by the FDA as a “generally regarded as safe”
excipient, and since it is hydrophilic can aid the solubilisation
of poorly water soluble drugs. Variation in the molecular weight
of the polymer can result in tuning of the drug release proper-
ties from PEO composites.26 Furthermore, SA has been exploited
for many years as a pH-responsive drug release system.27–29 In
this work, these properties were exploited to develop drug
delivery systems based on PEO–SA blend bres, with sodium
ibuprofen employed as a model drug.
Experimental
Electrospinning
Fibres were prepared by co-dissolving PEO (Sigma; MW ca.
400 000) and SA (Fisher; MW 120 000–190 000) in deionised
water to give nal concentrations of 5% and 1.5% w/v respec-
tively. 10 mL of this solution was then combined with varied
amounts of sodium ibuprofen (SI; Sigma-Aldrich; 98%). Analo-
gous solutions were prepared with varied SA concentrations. This
resulted in a series of spinning solutions as detailed in Table 1.
Each solution was carefully loaded into a 5 mL syringe, with
great care taken to avoid any air bubbles. The syringe was tted
with a metal needle tip (spinneret; internal diameter 0.84 mm),
and the positive electrode of a high voltage DC power supply
(HCP 35-65000, Fug Elektronik, Rosenheim, Germany) con-
nected to the spinneret. The grounded electrode was connected
to a metal collector (17  17 cm2) wrapped with aluminium foil.
The humidity of the spinning chamber was maintained belowThis journal is © The Royal Society of Chemistry 201420%, and its temperature at 37  2 C. The feed rate was
maintained at 0.5 mL h1 using a syringe pump (KDS100, Cole-
Parmer, Vernon Hills, IL, USA). The spinneret to collector
distance was 13 cm and the applied voltage 20 kV.
Characterisation
Fibre morphology and composition. The bres were visual-
ised using scanning electron microscopy on a JSM-5600LV
instrument (JEOL, Tokyo, Japan) or a Quanta 200 FEG ESEM
(FEI, Hillsborough, OR, USA). Samples were gold sputtered prior
to examination. The images obtained were analysed using the
ImageJ soware (National Institutes of Health, Bethesda, MD,
USA); bre diameters were measured at over 50 locations and
these data used to determine their average size. The results are
reported as mean  S.D. Scanning transmission electron
microcopy was additionally performed on selected samples with
the aid of a JEM-3000F HR (S)TEM (JEOL, Tokyo, Japan) oper-
ating at 300 kV. X-ray photoelectron spectroscopy was performed
at the NEXUS facility (Newcastle University). A K-alpha instru-
ment (Thermo Scientic, East Grinsted, UK) equipped with a
monochromated Al Ka X-ray source was used with a pass energy
of 40 eV and step size of 0.1 eV. Spectra were processed using the
CasaXPS soware (Casa Soware Ltd., Teignmouth, UK).
The structure of the SI post-electrospinning was probed by
nuclear magnetic resonance (NMR). Spectra were recorded at
ambient temperature, on an Avance-500 instrument
(1H frequency: 500.13 MHz; Bruker, Karlsruhe, Germany).
Samples were dissolved in D2O prior to measurement. The drug
loading in the bres was determined using high-performance
liquid chromatography (HPLC; 1260 Innity instrument, Agi-
lent, Santa Clara, CA, USA). The stationary phase comprised a
Supleco® Discovery HS F5 HPLC column (5 mmparticle size, 150
 4.6 mm) and the mobile phase was acetonitrile–0.1% TFA.
Elution was carried out isocratically (74 : 26) with a ow rate of
1.0 mL min1 and injection volume of 10 mL. The SI concen-
tration was assayed at 264 nm at room temperature.
Physical form and component interactions
The physical form of the components in the bres was probed
by diﬀraction and calorimetry. Powder X-ray diﬀraction (XRD)
was undertaken with a MiniFlex 600 diﬀractometer (RigaKu,J. Mater. Chem. B, 2014, 2, 1400–1407 | 1401
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View Article OnlineTokyo, Japan) using Cu Ka radiation at 40 kV and 15 mA.
Diﬀerential scanning calorimetry was performed with the aid of
a DSC Q2000 instrument (TA Instruments, New Castle, DE,
USA). Samples were heated from 25 to 150 C at 10 C min1
under a ow of nitrogen (50 mL min1).
The interactions between the components in the bres were
explored by IR spectroscopy (Spectrum 100 spectrometer, Per-
kin Elmer, Waltham, MA, USA) over the range 650–4000 cm1
with a resolution of 1 cm1.Drug release
0.15–0.4 g (depending on SI loading) of the bre structure was
immersed in 1 L of a release uid (either a pH 3 acetic acid
solution, or a phosphate buﬀer at pH 6.8) and stirred at 50 rpm
and 37 C on a dissolution apparatus (SR8 Plus, Hanson
Research, Chatsworth, CA, USA). Aliquots were removed at
regular intervals and the SI content determined by UV spec-
troscopy (UV1800, Shimadzu, Kyoto, Japan) at 264 nm. All
release studies were performed under sink conditions.Results and discussion
Fibre morphology
A photograph of the F1 bres (60.6% SI w/w) is given in Fig. 1(a).
It is immediately clear that the bres form a three-dimensional
“mountain” structure rather than a at mat on the collector
plate: our results thus agree with those of Bonino et al.24 Scan-
ning electron microscopy images were recorded on samples
taken from diﬀerent points of the 3D bre structure (base,
middle, and tip); data for the base and tip are included in Fig. 1.
The SEM data show the bres throughout the 3D structure to
have smooth and uniform structures. There is no obviousFig. 1 Images of the F1 and F2 ﬁbres. (a) Digital photograph of F1; (b an
showing the exterior of the tip of the F1 3D ﬁbre network; (e) SEM image
F2 collected on a lacey C coated Cu grid.
1402 | J. Mater. Chem. B, 2014, 2, 1400–1407“bead-on-string”morphology visible in any of the images. Each
bre appears to have a constant diameter, although there seems
to be a diﬀerence in size between the top and bottom of the
structure (318  53 and 233  44 nm respectively). Looking at
the outside of the structure, there are no visible particles;
however, bisection through the centre reveals a number of small
particles inside the structure at its apex (see Fig. 1(e)). The F2
and F3 bres (23.5 and 13.3% SI w/w respectively) exhibited
analogous features, with F2 having diameters of 271  42 nm
(top) and 209  48 nm (base) and F3 sizes of 260  42 nm (top)
and 205  53 nm (base). There thus appears to be a decline in
bre diameter as the SI content is reduced.
The observation of core–shell structure by Ma25 led us to
record scanning transmission electron microscopy (STEM)
images of the bres (Fig. 1(f)). No core–shell structure is visible
in any of the bres, but there are regions of high- and low-
contrast present throughout the bres.
X-ray photoelectron spectroscopy (XPS) was invoked to probe
the nature of the bre surfaces further. XPS spectra of the
starting materials (SI, SA, and PEO) were recorded, as were the
spectra of the bre materials. The C 1s spectra of the bres were
then peak tted using the C 1s spectra of the starting materials
as references to determine the relative amounts of eachmaterial
at the bre surfaces. The results of this analysis are given in
Table 2. The data for the blank F0 (PEO–SA only) bres show
that the surface comprises almost entirely PEO, in agreement
with the results observed by Ma et al.,25 although even with
these bres we see no core–shell structure by STEM. The frac-
tions of the surface comprising SI are, within the error of the
measurements, identical to those calculated from the weight
ratios of the components. However, for F1–F3 the SA fraction at
the surface is greater than that calculated from the starting
material weight ratios, while the PEO percentage is lower.d c) SEM images of the base of the F1 3D structure; (d) an SEM image
of the interior of the ﬁbre structure's apex; (f) STEM data for a sample of
This journal is © The Royal Society of Chemistry 2014
Table 2 The ratios of PEO, SA, and SI at the surface of the ﬁbres,
calculated from XPS data. Samples were taken from the top of the 3D
ﬁbre structure
Fibre ID
% SI
in bre (w/w)
Fractional composition (%)
PEO SA SI
F0 0 99.3  1.1 0.7  1.1 —
F1 60.6 15.0  1.2 24.0  2.0 60.3  3.0
F2 23.5 37.0  1.0 38.7  1.9 24.3  1.5
F3 13.3 49.0  7.8 39.0  9.0 12.0  2.5
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View Article OnlineAlthough no core–shell structure could be seen by STEM, the
XPS data indicate that there is some aggregation of SA at the
bre surface as proposed by Bonino et al.21,24X-ray diﬀraction
X-ray diﬀraction (XRD) patterns for samples taken from the top
and bottom of the F1 and F2 structures are given in Fig. 2,
together with patterns for the starting materials. PEO is a
crystalline polymer, and hence shows two distinct reections at
19 and 23. SI is also crystalline, and exhibits numerous
reections. SA is amorphous (see ESI, Fig. S1†). Both the top and
base of the F1 structure show the presence of a number of Bragg
reections (see Fig. 2(a)). These appear to occur at approxi-
mately the same positions as the SI and PEO reections,
although the reections are considerably broadened and also
shied to higher angle. The increased broadness of the SI
reections is consistent with the presence of SI crystallites with
reduced size (cf. the pure drug) in the bre structure. This is also
seen in the SEM data; the size of the particles which can be
observed in Fig. 1(e) is found to be ca. 1295  229 nm. Prior to
dissolution and electrospinning, the SI particles had sizes of
approximately 3  1.5 mm and hence there has been a signi-
cant reduction in particle size as a result of the processing. The
reason for the shi to higher angle is more puzzling, but is
tentatively assigned to the possible removal of defects in the SI
structure and/or changes in the stress within the particles as a
result of the electrospinning process. The reections corre-
sponding to PEO also shi. This must be a result of the incor-
poration of SA and SI into the PEO lattice, causing itsFig. 2 XRD patterns of the top and base of (a) the F1 structure (60.6% SI) a
be amorphous by X-ray diﬀraction (see Fig. S1†).
This journal is © The Royal Society of Chemistry 2014parameters to change. The XRD patterns for F2 and F3 also
show shis in the peak positions of PEO (see Fig. 2(b) for data
on F2), although the reections corresponding to SI can no
longer be clearly resolved as a result of the reduction in its
content.
Diﬀerential scanning calorimetry
Diﬀerential scanning calorimetry (DSC) data conrm the pres-
ence of crystalline SI and PEO in the bres. DSC traces of the
raw materials reveal melting endotherms, for SI at 100.3 C and
for PEO at 69.3 C. Data for F1 and F2 can be found in Fig. 3. The
traces exhibit a sharp endotherm at 62–63 C, attributed to the
melting of PEO. It is thus clear that the PEO retains its crys-
talline nature upon incorporation into bres. A second sharp
endotherm is visible at 92.5–93.5 C; this latter feature is
superimposed on a broad endotherm with an apex at ca. 105–
110 C. These two features are respectively believed to corre-
spond to the SI melting peak, and the loss of water (incomplete
evaporation of the water solvent used for electrospinning will
result in some being incorporated into the bres). SA melts at
T > 300 C, and hence is not seen in the DSC traces.
There are no signicant diﬀerences in the DSC behaviour of
the top and bottom of the bre structures. The presence of very
distinct SI and PEO melting endotherms conrms both to be
present in a crystalline form throughout the materials.
FTIR spectroscopy
FTIR spectra for F1, PEO, SA and SI are included in Fig. 4,
together with the chemical structures of the constituent
components of the bres. The spectrum of SI contains distinct
peaks around 3000–3500 cm1 (H-bonded OH stretches, arising
from the presence of some water in the material), 3000–
2850 cm1 (alkane C–H stretches), and characteristic peaks at
1545 and 1408 cm1 (respectively asymmetric and symmetric
carboxylate stretches). The SA spectrum also shows a broad
band from ca. 3700–2850 cm1, corresponding to H-bonded OH
groups and C–H stretches. Carboxylate peaks can be seen at
1589 and 1403 cm1, and C–O vibrations are at 1020 cm1. The
PEO spectrum has a distinct peak at ca. 2875 cm1 arising from
C–H stretches, and the C–O stretch is centred around
1095 cm1. The spectra recorded from the top and bottom of F1nd (b) F2 (23.5% SI), together with those of PEO and SI. SA was found to
J. Mater. Chem. B, 2014, 2, 1400–1407 | 1403
Fig. 4 (a) The chemical structure of the materials used in this study [top left: SI; top right: PEO; bottom: SA], and (b) IR spectra of the F1 ﬁbres and
associated starting materials.
Fig. 3 DSC traces of the top and base of (a) the F1 structure (60.6% SI), and (b) the F2 structure (23.5% SI).
Journal of Materials Chemistry B Paper
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View Article Onlineare essentially identical, and contain features from each of the
component species. A broad feature from 3500–3000 cm1
arises from H-bonded OH groups, and peaks at 2950 and
2875 cm1 from the SI and SA alkyl C–H bonds. The SI
carboxylate groups are visible at 1549 and 1408 cm1. Although
the latter has not moved, the asymmetric stretch has shied in
wavenumber, indicating the existence of interactions between
SI and the other components of the bres. The PEO C–O stretch
is seen at 1095 cm1.
Overall, therefore, the IR data indicate the successful incor-
poration of all three components into the bres, and suggest
that SI is interacting with the other components, most likely
through the formation of H-bonds. The IR spectra of the other
materials show largely analogous features, conrming the
successful formulation of bres containing all three compo-
nents intact.
NMR spectroscopy and drug loading
NMR spectroscopy was performed on samples of the bre mats
dissolved in D2O. The spectra aer dissolution are observed to
contain all the features of the SI starting material (see ESI,
Fig. S2†), conrming that the structural integrity of the drug
molecule is retained aer electrospinning. The drug loading
into the bres was also veried by HPLC, and found to be 100%
within the error of themeasurement (for F1, the values observed
were 101 2.1% for the top of the bre structure and 99 1.7%
for the base).1404 | J. Mater. Chem. B, 2014, 2, 1400–1407Drug release studies
Since the SI remains intact aer spinning, the bre structures
may have utility as drug delivery systems. Drug release was
studied in two diﬀerent pH milieu: a pH 3 acetic acid solution
(representative of the pH at the boundary between the fundic
and lower stomach, and typical of stomach pH in the fed state
or in the elderly) and a pH 6.8 phosphate buﬀer mimicking the
small intestine. 0.15–0.4 g (depending on SI loading) of the bre
structure was immersed in 1 L of the release uid and stirred at
50 rpm and 37 C. Aliquots were removed at regular intervals
and the SI content determined by UV spectroscopy. The results
are depicted in Fig. 5.
At pH 3, a highly unusual two-stage pulsatile drug release
prole was observed: to the best of our knowledge, this has
never before been seen for electrospun nanobre systems.
Within the rst 5–10 min aer the bres are added to the
release medium, there is a very rapid burst release of drug.
The amount of drug released in this stage is dependent on
the SI content of the bres, with a greater burst release being
seen as the SI loading increases. There is then a plateau in
which almost no further drug is released for 85–120 min,
aer which SI is freed from the bres at an almost constant
rate over a further 50–200 min, depending on the bre
loading. The F1–F3 bres thus comprise time-controlled
pulsatile drug delivery systems, where there is an “on/oﬀ”
pattern of drug release (bursts of release with a lag period
between them).This journal is © The Royal Society of Chemistry 2014
Fig. 5 Ibuprofen release from the nanoﬁbres at (a) pH 3 and (b) pH 6.8. Fibres F1 ( ), F2 ( ) and F3 ( ) are shown; these contain respectively 60.6,
23.5, and 13.3% w/w SI. Three independent experiments were performed (each with a separate ﬁbre mat), and results are reported as mean S.D.
Fig. 6 Drug release from ﬁbres with varied SA contents at pH 3: F4
(6.3% SA; ); F1 (9.1% SA; ); F5 (11.8% SA; ); and, F6 (14.3% SA; ).
For clarity, data are shown out only to 400 min, although experiments
were performed for up to three days. Three independent experiments
were performed (each with a separate ﬁbre mat), and results are
reported as mean  S.D.
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View Article OnlineIn contrast, in the pH 6.8 buﬀer, rapid SI release over ca. 15
min is seen, with essentially identical release proles regardless
of the SI loading in the bres. pH 3 is typical of stomach pH
when in the fed state. By appropriate selection of the bre
composition it would be possible to deliver a desired loading
dose of drug in the stomach, with the remainder retained in the
bres for longer than the typical stomach transit time (2 h) and
releasing rapidly upon entry to the intestinal tract. The
percentage of SI released in the rst stage is approximately the
same as the w/w percentage of SI in the bres, meaning it would
be facile to design materials to release a given amount of SI in
the stomach. The formulation acts as a dual trigger release
system, and can be activated by both pH and time. This could
provide a failsafe approach for pulsatile release in patients with
signicantly longer gastric residence times, or where the
intestinal pH is not high enough for the formulation to release
the second part of its drug loading. In such cases the drug will
still be released aer a time delay, which can be tuned into the
formulation to achieve the desired pharmacokinetic prole.
Given that the extent of burst release can be tuned by varying
the SI content, experiments were also performed in which the
content of SA in the bres was varied. F1 contains 9.1% SA w/w,
and materials were prepared with the same amount of SI in the
starting solutions, but yielding products with 6.3, 11.8, and
14.3% SA w/w (F4, 5, and 6 respectively; see Table 1). In all cases,
3D “mountain” structures were deposited on the collector plate.
The release proles obtained at pH 3 are given in Fig. 6. The
initial burst release is observed to be ca. 60% for all SA contents
(approximately the same as the SI loading in the bres), but
with increasing SA content the second phase of release is
retarded. With 6.3% SA (F4) the plateau lasts for some 45 min,
whereas with 14.3% SA (F6) it is greater than 7 hours, and even
aer 3 days of release only around 75% of the embedded drug
was released. It is therefore possible to exert very precise control
over the drug release characteristics: the SI content determines
the amount of drug released in the rst “burst” release, while
the SA content dictates the second stage of release.Fig. 7 SEM images of F1 ﬁbres exposed to a pH 3 environment for 10–
20 minutes. (a) The ﬁbre mat after immersion in a few drops of acidic
medium; (b) the mat after suspension in 1 L of medium. The inset in (b)
is an enlargement of a section of the main image, and the scale bar
represents 500 nm.Drug release mechanism
The trends identied above can be explained by a simple model.
The STEM data indicate that there are regions of the bresThis journal is © The Royal Society of Chemistry 2014which are relatively high contrast, and others where less
contrast is present. This suggests that there may be some areas
of the bres which are more SA rich than others. SI particles are
also seen to be present at the bre surfaces by SEM. PEO is freely
soluble at pH 3, while SA is not. The dissolution experimentsJ. Mater. Chem. B, 2014, 2, 1400–1407 | 1405
Fig. 8 A schematic illustrating the proposed mechanism responsible for the two-stage pulsatile drug release observed at pH 3.
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View Article Onlinewere performed under sink conditions, and hence the SI will
also be freely soluble. We can therefore hypothesise that SI
particles on the surface, and also SI ion pairs at the bre edges,
are freed into solution very rapidly at this low pH. At the same
time the PEO molecules will disentangle and begin to dissolve,
freeing the SI linked to PEO through an erosion mechanism.
The greater the SI content, the more SI which exists as particles
or near the surface, and hence the larger the percentage of drug
released in the initial burst phase.
The SA will be insoluble at pH 3, and so its strands might be
expected to cluster together while the other components of the
bre dissolve. Similar results have been reported in the litera-
ture: SA is known to aggregate at low pH (ca. 3) into core–shell
micelle-like structures.30 The diﬀerent residues in SA have
diﬀerent pKa values (3.38 and 3.64 respectively for the b-D-
mannuronic and a-L-guluronic acids31), which results in some
portions of its polymer chain becoming hydrophobic and others
hydrophilic at this low pH. We hypothesised that such eﬀects
might also be involved in the bre systems. To explore this, F1
bres were exposed to the pH 3 medium for 10–20 minutes
(suﬃcient time for the rst release stage to be complete),
recovered by ltration, and assessed by SEM. Experiments were
performed both in which the bres were immersed in 1 L of the
pH 3 solution, and where they were treated with only a few
drops of this solution. The results are given in Fig. 7.
The images shows that upon addition of the pH 3 medium,
the bres swell (Fig. 7(a)) and begin to dissolve and disentangle
(Fig. 7(b)) as the PEO absorbs water. In the centre of the image
in Fig. 7(a), where individual bres can be resolved, the bre
diameter is of the order of 140–250 nm, somewhat smaller than
the initial material. Upon exposure to a larger volume of the
acidic medium (Fig. 7(b)), the diameter declines further, to
around 100 nm. Small particles can also be seen in both images.
Although it is uncertain exactly what the nature of the particles
visible in Fig. 7 is (they may be crystals of neutral ibuprofen or
possibly undissolved SI, although the latter is unlikely in Fig
7(b) where the experiment was performed in sink conditions
and the SI will be highly soluble) it is thought that SA aggregates1406 | J. Mater. Chem. B, 2014, 2, 1400–1407also form from the PEO–SA–SI bres, whether they be micelle-
like or larger linear aggregates reminiscent of the original bre
structure. The low solubility of SA at pH 3 means that SI in
SA-rich areas of the bres is hindered in dissolution. However,
because the bres comprise blends of PEO and SA, with PEO
present in greater amounts, it appears that the swelling and
dissolution of the PEO upon prolonged exposure to the acetate
solution is suﬃcient to cause the SA strands eventually to
separate suﬃciently to free the SI associated with them, at least
with lower SA contents. Increased SA contents result in the
formation of more robust aggregates, and hence as this
increases so does the time before which the nal stage of drug
release begins.
This model is consistent with all the observed results, and is
depicted in Fig. 8. At pH 6.8 both PEO and SA are freely soluble,
and so the bre mat dissolves completely, releasing all the
embedded SI very rapidly.
Conclusions
This paper reports for the rst time blended bres containing
PEO, sodium alginate and sodium ibuprofen. The as-formed
bre aggregates exhibit novel 3D network structures, and at pH
3 two-stage pulsatile drug release is seen. The release prole
may be precisely tuned by varying the sodium alginate and
sodium ibuprofen contents of the bres. The materials may
hence be used for pulsatile drug release into the stomach in the
fed state, or in elderly patients.
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